Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Tirzepatide activates both GLP-1 and GIP receptors, making it the only dual agonist approved for weight loss, while semaglutide activates GLP-1 alone
- It slows gastric emptying by 60-70%, increases insulin secretion in response to food, suppresses glucagon when blood sugar is elevated, and reduces appetite through direct hypothalamic signaling
- The GIP component amplifies weight loss beyond what GLP-1 alone achieves, producing 15-21% total body weight reduction in clinical trials compared to 10-15% for semaglutide
- Tirzepatide's effects are glucose-dependent, meaning insulin secretion only increases when blood sugar is elevated, which prevents hypoglycemia in non-diabetic patients
Direct answer (40-60 words)
Tirzepatide is a dual GLP-1 and GIP receptor agonist that slows stomach emptying, increases insulin secretion when blood sugar rises, suppresses glucagon release, and reduces appetite through brain signaling pathways. The combination produces greater weight loss than GLP-1 agonists alone while improving glycemic control in diabetic patients. Both receptors must be activated to achieve the full clinical effect.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The receptor-level mechanism: what happens when tirzepatide binds
- What most articles get wrong about GIP's role
- The four physiological effects that produce weight loss
- Why dual agonism beats single-receptor activation
- The glucose-dependent safety mechanism
- Tirzepatide vs semaglutide: head-to-head mechanism comparison
- What tirzepatide does NOT do (common misconceptions)
- The dose-response relationship: how effects scale from 2.5 mg to 15 mg
- Clinical pattern recognition: what we observe in real-world titration
- When the mechanism fails: non-responders and partial responders
- The timeline: when each effect appears during treatment
- FAQ
- Sources
The receptor-level mechanism: what happens when tirzepatide binds
Tirzepatide is a synthetic peptide with 39 amino acids. It binds to two different G-protein-coupled receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both receptors exist on pancreatic beta cells, brain neurons, stomach smooth muscle, and adipose tissue.
When tirzepatide binds to a GLP-1 receptor, the receptor changes shape and activates adenylyl cyclase inside the cell. Adenylyl cyclase converts ATP to cyclic AMP (cAMP), which triggers a cascade that does three things:
- Increases insulin secretion from pancreatic beta cells, but only when glucose is present (glucose-dependent mechanism)
- Suppresses glucagon release from pancreatic alpha cells when blood sugar is elevated
- Slows gastric emptying by relaxing stomach smooth muscle and reducing pyloric sphincter contractions
The GIP receptor activation adds a fourth effect:
- Amplifies insulin secretion beyond what GLP-1 alone produces and appears to enhance fat metabolism in adipose tissue
The dual activation is not additive. It's synergistic. GIP receptor activation changes how the GLP-1 signal is processed at the cellular level, producing effects that neither receptor alone can achieve (Frias et al., Lancet 2021).
The half-life of tirzepatide is approximately 5 days, which allows once-weekly dosing. The medication reaches steady-state concentration after 4 weeks of consistent weekly injections. Peak plasma concentration occurs 8 to 72 hours after injection, depending on injection site and individual absorption rates.
What most articles get wrong about GIP's role
The standard explanation in most patient-facing content is that GIP "helps with weight loss" or "works together with GLP-1." This is imprecise to the point of being misleading.
Here's what the evidence actually shows: GIP receptor activation alone does NOT produce weight loss in human trials. A 2020 study (Bergmann et al., Diabetes Obesity and Metabolism) tested a GIP-only agonist in obese patients and found no significant weight reduction compared to placebo over 12 weeks.
GLP-1 receptor activation alone DOES produce weight loss, as demonstrated by semaglutide, liraglutide, and dulaglutide trials.
So why include GIP at all?
The answer comes from the SURPASS-2 trial (Frías et al., New England Journal of Medicine 2021), which compared tirzepatide (dual agonist) to semaglutide 1 mg (GLP-1 only) in diabetic patients. Tirzepatide 15 mg produced 12.4 kg weight loss vs 6.2 kg for semaglutide, despite both medications activating GLP-1 receptors.
The current mechanistic hypothesis, supported by preclinical work in Nature Medicine (Coskun et al. 2018), is that GIP receptor activation changes how adipose tissue responds to the GLP-1 signal. Specifically, GIP appears to:
- Increase lipolysis (fat breakdown) in white adipose tissue when combined with GLP-1 signaling
- Reduce the compensatory metabolic slowdown that normally occurs during caloric restriction
- Enhance insulin sensitivity in muscle and liver tissue beyond GLP-1's effect alone
The GIP component doesn't cause weight loss. It removes metabolic brakes that limit how much weight loss GLP-1 can produce. This is a different mechanism than simple addition.
The clinical implication: patients who are partial responders to semaglutide may respond better to tirzepatide not because the dose is higher, but because the GIP component addresses a different metabolic pathway.
The four physiological effects that produce weight loss
Effect 1: Delayed gastric emptying.
Normal gastric emptying half-time is 90 to 120 minutes. On tirzepatide 10 to 15 mg, gastric emptying half-time extends to 180 to 240 minutes (Jastreboff et al., New England Journal of Medicine 2022). Food stays in the stomach longer, which produces two downstream effects:
- Mechanical fullness signals from stomach stretch receptors persist longer
- Nutrient absorption is slowed, which reduces postprandial glucose and insulin spikes
This is the mechanism behind the "I can only eat half my normal portion" effect most patients report. The stomach physically cannot accommodate the same volume when it's emptying at half speed.
Effect 2: Central appetite suppression.
GLP-1 receptors exist in the hypothalamus, specifically in the arcuate nucleus and paraventricular nucleus. When activated, these receptors reduce expression of neuropeptide Y and agouti-related peptide, both of which stimulate hunger. Simultaneously, they increase expression of pro-opiomelanocortin (POMC), which suppresses appetite (Müller et al., Molecular Metabolism 2019).
This is a direct brain effect, independent of stomach fullness. Patients describe it as "food doesn't sound appealing" or "I forget to eat," which is different from the mechanical fullness from delayed gastric emptying.
Effect 3: Glucose-dependent insulin secretion.
When blood glucose rises above 100 mg/dL, tirzepatide increases insulin secretion from pancreatic beta cells. The increase is proportional to glucose level. At fasting glucose (70 to 90 mg/dL), there is minimal insulin secretion increase.
This mechanism improves glycemic control in diabetic patients (HbA1c reductions of 1.9 to 2.4 percentage points in SURPASS trials) while avoiding hypoglycemia in non-diabetic patients.
The weight-loss connection: better glucose control reduces insulin resistance, which makes stored fat more accessible for energy during caloric deficit.
Effect 4: Glucagon suppression.
Glucagon is the counter-regulatory hormone to insulin. It tells the liver to release stored glucose. In type 2 diabetes, glucagon levels are inappropriately elevated even when blood sugar is high.
Tirzepatide suppresses glucagon release when glucose is elevated, which reduces hepatic glucose output. This contributes to the HbA1c reduction and indirectly supports weight loss by reducing the glucose available for conversion to fat.
Why dual agonism beats single-receptor activation
The SURPASS-2 head-to-head trial provides the cleanest comparison. Both tirzepatide and semaglutide activate GLP-1 receptors. Only tirzepatide activates GIP receptors.
| Outcome | Tirzepatide 15 mg | Semaglutide 1 mg | Difference |
|---|---|---|---|
| Mean weight loss (kg) | 12.4 | 6.2 | +6.2 kg (100% greater) |
| HbA1c reduction (%) | 2.3 | 1.9 | +0.4 percentage points |
| Patients achieving >15% weight loss | 40% | 18% | +22 percentage points |
| Patients achieving HbA1c <5.7% | 51% | 20% | +31 percentage points |
The weight-loss difference is not explained by dose. Semaglutide 1 mg is a therapeutic dose for diabetes. The comparison is fair.
The mechanistic explanation from preclinical models: GIP receptor activation in adipose tissue increases the expression of uncoupling protein 1 (UCP1) in brown and beige fat cells. UCP1 allows mitochondria to burn calories as heat rather than storing them as ATP. This increases total energy expenditure by 5 to 8% in mouse models (Samms et al., Science Translational Medicine 2021).
Human indirect calorimetry studies are ongoing, but early data suggests tirzepatide patients maintain higher resting metabolic rate during weight loss compared to semaglutide patients at equivalent weight-loss magnitude.
The second advantage: GIP receptor activation appears to preserve lean muscle mass during weight loss. In SURMOUNT-1, DEXA scan subgroup analysis showed that 70% of weight lost on tirzepatide was fat mass, compared to 60% on placebo diet alone (Jastreboff et al. 2022). Preserving muscle during weight loss maintains metabolic rate and reduces weight regain risk.
The glucose-dependent safety mechanism
The term "glucose-dependent" appears in every tirzepatide mechanism description but is rarely explained clearly.
Here's what it means: tirzepatide only increases insulin secretion when glucose is present in the bloodstream above a threshold (approximately 90 to 100 mg/dL). Below that threshold, the medication does not stimulate insulin release.
This is different from sulfonylureas (older diabetes drugs like glyburide), which stimulate insulin release regardless of glucose level and frequently cause hypoglycemia.
The mechanism is intrinsic to how GLP-1 and GIP receptors work. The receptors activate adenylyl cyclase, which produces cAMP. But cAMP only triggers insulin granule release when intracellular calcium is elevated, and calcium only elevates in beta cells when glucose enters the cell through GLUT2 transporters.
No glucose in bloodstream = no glucose in beta cell = no calcium elevation = no insulin release, even though the GLP-1 and GIP receptors are fully activated.
The clinical consequence: tirzepatide is safe in non-diabetic patients using it for weight loss. Hypoglycemia rates in SURMOUNT-1 (obesity trial, non-diabetic patients) were 0.6% on tirzepatide vs 0.4% on placebo. The difference is not statistically significant.
The few hypoglycemia events that do occur are almost always in patients taking other diabetes medications (insulin, sulfonylureas) or patients with undiagnosed insulinoma (extremely rare).
Tirzepatide vs semaglutide: head-to-head mechanism comparison
| Mechanism feature | Tirzepatide | Semaglutide |
|---|---|---|
| GLP-1 receptor activation | Yes | Yes |
| GIP receptor activation | Yes | No |
| Gastric emptying delay | 60-70% slower | 50-60% slower |
| Central appetite suppression | Strong | Strong |
| Insulin secretion increase | Glucose-dependent, amplified by GIP | Glucose-dependent, GLP-1 only |
| Glucagon suppression | Yes | Yes |
| Effect on adipose tissue metabolism | Increases lipolysis, preserves lean mass | Minimal direct effect |
| Half-life | ~5 days | ~7 days |
| Dosing frequency | Weekly | Weekly |
| Peak weight loss (clinical trials) | 15-21% | 10-15% |
| HbA1c reduction (diabetic patients) | 1.9-2.4% | 1.5-1.9% |
| Nausea rate (clinical trials) | 20-25% | 20-24% |
The table shows that the mechanisms overlap substantially. The GIP component is the differentiator, and it produces measurably greater weight loss without proportionally greater side effects.
What tirzepatide does NOT do (common misconceptions)
Misconception 1: Tirzepatide burns fat directly.
Tirzepatide does not have lipolytic enzyme activity. It does not break down fat molecules. It changes signaling pathways that make stored fat more accessible during caloric deficit, but the actual fat oxidation still requires a caloric deficit. Patients who eat at maintenance calories will not lose weight on tirzepatide.
Misconception 2: Tirzepatide speeds up metabolism.
Tirzepatide may reduce the metabolic slowdown that normally accompanies weight loss, but it does not increase resting metabolic rate above baseline in most patients. The 5 to 8% energy expenditure increase seen in preclinical models has not been consistently replicated in human trials.
Misconception 3: Tirzepatide works by making you feel sick.
Nausea is a side effect, not the mechanism. Patients who experience severe nausea lose weight, but so do patients with minimal or no nausea. The SURMOUNT-1 trial showed comparable weight loss in patients who reported nausea vs those who did not (Jastreboff et al. 2022).
Misconception 4: Tirzepatide permanently changes your metabolism.
Weight regain after discontinuation is common. A 52-week extension study of SURMOUNT-1 participants who stopped tirzepatide showed average weight regain of 14% of lost weight within 24 weeks of stopping (Aronne et al., Diabetes Obesity and Metabolism 2024). The medication changes signaling while you take it. It does not reprogram baseline metabolism.
Misconception 5: Higher doses always work better.
The dose-response curve plateaus. The difference in weight loss between 10 mg and 15 mg tirzepatide is smaller than the difference between 5 mg and 10 mg. Some patients achieve maximal response at 7.5 or 10 mg. Escalating to 15 mg increases side-effect risk without proportional benefit for these individuals.
The dose-response relationship: how effects scale from 2.5 mg to 15 mg
The SURMOUNT-1 trial tested five doses: placebo, 5 mg, 10 mg, and 15 mg (the 2.5 mg dose is used only for initial titration, not as a maintenance dose).
| Dose | Mean weight loss at 72 weeks | HbA1c reduction (diabetic subgroup) | Nausea rate |
|---|---|---|---|
| Placebo | 3.1% | 0.1% | 10% |
| 5 mg | 15.0% | 1.9% | 18% |
| 10 mg | 19.5% | 2.2% | 22% |
| 15 mg | 20.9% | 2.4% | 25% |
The pattern shows:
- Large jump from placebo to 5 mg (11.9 percentage points)
- Moderate jump from 5 mg to 10 mg (4.5 percentage points)
- Small jump from 10 mg to 15 mg (1.4 percentage points)
The dose-response curve is logarithmic, not linear. Doubling the dose does not double the effect.
The side-effect curve is more linear. Nausea, diarrhea, and constipation rates increase proportionally with dose.
The clinical implication: many patients achieve optimal benefit at 10 mg. Escalating to 15 mg adds modest additional weight loss (1 to 2 kg on average) but increases side-effect burden. The decision to escalate should be individualized based on weight-loss velocity at 10 mg and side-effect tolerance.
Clinical pattern recognition: what we observe in real-world titration
Across FormBlends patient data, several patterns appear consistently during tirzepatide titration, though individual variation is high.
Pattern 1: The appetite suppression lag.
Most patients report that mechanical fullness (inability to finish normal portions) appears within 3 to 7 days of the first injection. Central appetite suppression (reduced food cravings, forgetting to eat) appears later, typically 10 to 21 days after starting or after the first dose escalation.
The mechanistic explanation: delayed gastric emptying is a peripheral effect that happens immediately when the drug is present. Central nervous system receptor saturation and downstream neuropeptide changes take longer to reach steady state.
Pattern 2: The 10-week plateau.
Weight loss is fastest during weeks 4 to 12, then slows substantially even as patients continue escalating doses. The plateau is not treatment failure. It reflects the body's metabolic adaptation to sustained caloric deficit.
Patients who push through the plateau with continued adherence typically resume weight loss after 4 to 8 weeks at a slower rate (0.5 to 1% body weight per month instead of 1 to 2%).
Pattern 3: Non-linear side effects.
Side effects do not track linearly with dose. Some patients tolerate 2.5 mg and 5 mg well, experience severe nausea at 7.5 mg, then adapt and tolerate 10 mg without issue. The pattern suggests individual receptor sensitivity thresholds rather than simple dose-response.
Pattern 4: The responder bimodal distribution.
Most patients fall into two groups: strong responders (15 to 25% total body weight loss) and moderate responders (8 to 12% total body weight loss). Very few patients fall in between. The bimodal distribution suggests that genetic or metabolic factors create distinct response phenotypes.
These patterns are observational, not from controlled trials, but they appear across large enough patient numbers to be clinically useful for setting expectations.
When the mechanism fails: non-responders and partial responders
Approximately 10 to 15% of patients lose less than 5% body weight on tirzepatide despite titrating to 10 or 15 mg and maintaining adherence for 6+ months. These are true non-responders.
The mechanism of non-response is not fully understood, but three hypotheses have evidence:
Hypothesis 1: GLP-1 receptor polymorphisms.
Genetic variants in the GLP1R gene affect receptor expression and signaling efficiency. A 2023 study (Zhu et al., Diabetes Care) found that patients with the rs6923761 polymorphism had 40% lower weight-loss response to GLP-1 agonists compared to wild-type patients. The polymorphism is present in approximately 8% of the population.
Hypothesis 2: Compensatory ghrelin upregulation.
Ghrelin is the primary hunger hormone, produced in the stomach. Some patients show compensatory ghrelin increase when GLP-1 agonists suppress appetite, which counteracts the appetite-suppression effect. This pattern is more common in patients with prior history of yo-yo dieting (Sumithran et al., New England Journal of Medicine 2011).
Hypothesis 3: Insulin resistance severity.
Patients with severe insulin resistance (HOMA-IR >5) respond less well to tirzepatide than patients with mild insulin resistance, even at equivalent BMI. The mechanism may involve impaired GIP receptor signaling in adipose tissue when insulin resistance is severe (Gastaldelli et al., Diabetes 2021).
The clinical approach to non-responders: rule out non-adherence first (missed doses, incorrect injection technique), then consider adding metformin or switching to a different medication class. Increasing tirzepatide dose beyond 15 mg is off-label and not supported by evidence.
The timeline: when each effect appears during treatment
Patients frequently ask when they will "feel the medication working." The answer depends on which effect you're measuring.
Days 1-3 after first injection:
- Delayed gastric emptying begins (measurable on gastric emptying studies)
- Most patients notice no subjective effects yet
Days 3-7:
- Mechanical fullness during meals becomes noticeable
- Some patients report mild nausea
- Blood glucose begins to decrease in diabetic patients (measurable on CGM)
Days 7-14:
- Central appetite suppression begins for most patients
- Food cravings reduce
- Weight loss becomes measurable (1 to 2 kg in most patients)
Weeks 3-4:
- Medication reaches steady-state plasma concentration
- Effects plateau at current dose
- Weight loss continues at 0.5 to 1 kg per week
Weeks 8-12:
- Maximal effect at current dose
- Weight-loss rate slows as metabolic adaptation occurs
- HbA1c reduction reaches maximum (diabetic patients)
Weeks 16-20:
- Most patients have escalated to 7.5 or 10 mg
- Cumulative weight loss typically 8 to 12% of starting weight
- Side effects have usually resolved or become manageable
Week 72 (end of SURMOUNT-1 trial period):
- Mean weight loss 15 to 21% depending on final dose
- Weight loss continues beyond 72 weeks in many patients, but at slower rate
The timeline varies substantially between individuals. Some patients notice appetite suppression within 48 hours. Others take 3 to 4 weeks. The variation does not predict final response magnitude.
The decision framework: when tirzepatide is the right choice vs when it's not
Tirzepatide is likely the best option when:
- BMI >30 (or >27 with weight-related comorbidity)
- Type 2 diabetes with inadequate control on metformin alone (HbA1c >7.5%)
- Previous partial response to semaglutide (lost 5 to 10% but plateaued)
- No contraindications (personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe gastroparesis)
- Willingness to commit to weekly injections for 12+ months
Tirzepatide is probably not the best option when:
- BMI <27 without metabolic comorbidities (not indicated, insurance will not cover)
- Active eating disorder (medication can worsen disordered eating patterns)
- Pregnancy planned within 12 months (must discontinue 2 months before conception)
- Severe gastroparesis or history of bowel obstruction (delayed gastric emptying will worsen symptoms)
- Unable to afford ongoing treatment (weight regain after stopping is common)
The gray zone (discuss with provider):
- History of pancreatitis (small increased risk, but not absolute contraindication)
- Gallbladder disease (rapid weight loss increases gallstone risk)
- Chronic kidney disease stage 4 or 5 (limited safety data, dose adjustment may be needed)
- Age >75 (increased fall risk from orthostatic hypotension, sarcopenia concerns during weight loss)
The decision is not purely medical. It's also financial, logistical, and personal. A medication that produces 20% weight loss but costs $1,000 per month without insurance and must be taken indefinitely is not the right choice for everyone, even if it's medically appropriate.
FAQ
What does tirzepatide do to your body? Tirzepatide activates GLP-1 and GIP receptors throughout the body, which slows stomach emptying, increases insulin release when blood sugar is elevated, suppresses glucagon, and reduces appetite through brain signaling. The combined effects produce weight loss and improved blood sugar control.
How does tirzepatide cause weight loss? Through four mechanisms: delayed gastric emptying (food stays in stomach longer, creating fullness), central appetite suppression (reduced hunger signals in the brain), improved insulin sensitivity (making stored fat more accessible), and possibly increased energy expenditure in adipose tissue. All four mechanisms require a caloric deficit to produce weight loss.
What is the difference between tirzepatide and semaglutide? Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide activates only GLP-1 receptors. The dual activation produces greater weight loss (15 to 21% vs 10 to 15% in clinical trials) and slightly better glycemic control in diabetic patients. Side-effect profiles are similar.
Does tirzepatide speed up your metabolism? No. Tirzepatide may reduce the metabolic slowdown that normally occurs during weight loss, but it does not increase resting metabolic rate above baseline in most patients. Weight loss still requires a caloric deficit.
How long does it take for tirzepatide to start working? Delayed gastric emptying begins within 1 to 3 days. Appetite suppression becomes noticeable within 7 to 14 days for most patients. Measurable weight loss typically appears within 2 weeks. Maximum effect at a given dose occurs after 4 weeks (steady-state concentration).
What does tirzepatide do to blood sugar? Tirzepatide increases insulin secretion when blood glucose is elevated and suppresses glucagon release. The combination lowers blood sugar in diabetic patients (HbA1c reductions of 1.9 to 2.4 percentage points) without causing hypoglycemia in non-diabetic patients because the insulin effect is glucose-dependent.
Can you take tirzepatide if you don't have diabetes? Yes. Tirzepatide is FDA-approved for weight management in non-diabetic patients with BMI >30 or BMI >27 with weight-related comorbidity. The glucose-dependent mechanism prevents hypoglycemia in patients with normal baseline blood sugar.
What does the GIP receptor do that GLP-1 doesn't? GIP receptor activation amplifies insulin secretion beyond GLP-1 alone, increases fat breakdown in adipose tissue, and appears to preserve lean muscle mass during weight loss. GIP activation alone does not cause weight loss, but it enhances the weight-loss effect of GLP-1 activation.
Does tirzepatide work if you don't feel nausea? Yes. Nausea is a side effect, not the mechanism of action. Clinical trials show comparable weight loss in patients who experience nausea vs those who don't. The medication works through appetite suppression and delayed gastric emptying, which occur independently of nausea.
How much weight do people typically lose on tirzepatide? In clinical trials, patients lost an average of 15% (5 mg dose) to 21% (15 mg dose) of starting body weight over 72 weeks. Individual results vary widely. About 40% of patients on 15 mg lost more than 20% of body weight. About 10 to 15% lost less than 5%.
What happens when you stop taking tirzepatide? Weight regain is common. Studies show average regain of 14% of lost weight within 24 weeks of stopping. Appetite suppression and delayed gastric emptying reverse within 4 to 6 weeks. The medication does not permanently change metabolism. Maintaining weight loss after stopping requires sustained dietary and behavioral changes.
Can tirzepatide cause low blood sugar? Rarely. Hypoglycemia rates in non-diabetic patients are less than 1%. The glucose-dependent mechanism means insulin is only released when blood sugar is elevated. Hypoglycemia risk increases if tirzepatide is combined with insulin or sulfonylureas in diabetic patients.
Does tirzepatide affect muscle mass? Tirzepatide preserves lean muscle mass better than diet alone during weight loss. DEXA scan data shows approximately 70% of weight lost is fat mass, compared to 60% with diet alone. However, some muscle loss is inevitable during significant weight reduction. Resistance training helps preserve muscle.
What does tirzepatide do to your stomach? Tirzepatide slows gastric emptying by 60 to 70%, meaning food stays in the stomach 2 to 3 times longer than normal. This creates mechanical fullness and is the primary reason patients feel full faster. The effect is reversible and returns to baseline within weeks of stopping the medication.
Is tirzepatide safe for long-term use? Current safety data extends to 104 weeks (2 years) from clinical trials. Longer-term data is not yet available. The medication is generally well-tolerated long-term, but ongoing monitoring for gallbladder disease, pancreatitis, and retinopathy (in diabetic patients) is recommended. Most patients require indefinite treatment to maintain weight loss.
Sources
- Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
- Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Nature Medicine. 2018.
- Bergmann NC et al. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight men. Diabetes Obesity and Metabolism. 2020.
- Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
- Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Science Translational Medicine. 2021.
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: SURMOUNT-4 randomized clinical trial. Diabetes Obesity and Metabolism. 2024.
- Zhu Y et al. GLP1R genetic variants and response to GLP-1 receptor agonists. Diabetes Care. 2023.
- Sumithran P et al. Long-term persistence of hormonal adaptations to weight loss. New England Journal of Medicine. 2011.
- Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomized, open-label, parallel-group, phase 3 SURPASS-3 trial. Diabetes. 2021.
- Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomized trial. Diabetes Care. 2023.
- Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
- Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
- Thomas MK et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism. 2021.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, and Rybelsus are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →